Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
A major consumer group has filed a complaint with the Competition and Markets Authority, alleging the pharmacy chains used inflated reference prices to make member discounts appear more substantial than they truly were.
While the energy sector retrenched amid falling crude prices, ExxonMobil executed a massive $20 billion share repurchase program in 2025, underlining its financial muscle and commitment to shareholder returns. The oil giant also reported earnings that beat estimates, driven by record production in the Permian Basin and Guyana, even as it takes a hardline stance on reinvesting in Venezuela.
An analysis of the most-held stocks on the Robinhood platform reveals where the retail investing crowd is placing its bets, with two tech giants emerging as particularly compelling long-term investments.
Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Pzena Investment Management's Focused Value Strategy lagged behind its benchmark in Q4 2025, with semiconductor firm Skyworks Solutions cited as a key detractor. The fund's commentary highlights the challenges for value investing in a market dominated by AI and mega-cap stocks.
Amid rising electricity prices and shifting federal incentives, solar platform GigaWatt is turning to crowd-investing to accelerate its push into integrated, user-friendly DIY solar kits, betting on AI and streamlined hardware to capture a growing market.
Investors who held shares in SouthGobi Resources Ltd. (CVE:SGQ) since 2019 have seen a staggering 486% return, a powerful case study in long-term equity investing despite recent volatility.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
The investment giant deepens its commitment to low-cost investing with sweeping expense ratio cuts across 53 funds, marking its largest two-year fee reduction on record.
Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.
Hong Kong apparel giant Crystal International is investing in a high-tech logistics center in China, aiming to slash fabric transfer times by 75% and power operations with solar energy as part of its broader smart manufacturing push.
Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.
With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.
Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
